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Abstract
Background: Iron deficiency anemia is a public health problem of a sizable proportion
in developing countries. Recently, emerging biochemical knowledge coupled with the
discovery of Hepcidin have greatly advanced our understanding of iron metabolism
and offered a better insight into its associated pathophysiology. This knowledge should
be applied to iron-deficiency anemia therapy to avoid subsequent sequelae of tissue
damage associated with reactive oxygen radicals that are catalyzed by iron, because
current practices do not include these advances in the treatment guidelines. In the light
of recent progress, the existing iron therapy program in many healthcare settings is
controversial. This necessitates adjusting the magnitude of iron dose with respect
to the very limited iron bioavailability, as gauged by Hepcidin. The current study
was therefore aimed to incorporate newly emerging biochemical knowledge into the
current iron-deficiency anemia treatment practice
Methods: Literature relevant to iron-deficiency studies published in English between
1964 and 2020 and available online was covered.
Conclusion: Evidently, the existing iron-therapy schedule is both inefficient and toxic.
The intricate metabolism of iron should be translated into a more rational iron
intervention program with special bias towards low- and middle-income countries
requiring a more individualized approach.
Keywords: iron deficiency anemia, hepcidin, oxidative stress, iron therapy
1. Introduction
Anemia is a worldwide health problem affecting one-third of the global population, and
iron-deficiency anemia (IDA) accounts for half of them [1, 2]. IDA affects populations of
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both developed and developing countries [3, 4]. The developing countries, categorized
by the World Bank as low- and middle-income countries (LMICs), present the highest
incidence as well as more severe anemia, especially in specific populations [1, 5]. The
LMICs lack efficient resource allocation; hence they form a large proportion of theworld’s
population with the greatest disease burden [6].6
Iron deficiency in LMICs is the most common micronutrient malnutrition. Its preva-
lence is high due to poverty that leads to lack of nutritious food, inadequate food
intake, inadequate healthcare, diseases, infections, and blood loss [7]. However, in the
developed countries, IDA is not a major health problem. In these countries, it only
endangers certain groups like young children, adolescents, pregnant women, elderly,
blood donors, vegetarians, endurance athletes, and migrants [8].
2. Materials and Methods
2.1. Impact of iron deficiency on the health of vulnerable population
Iron deficiency occurs when dietary iron intake cannot meet the iron needs over a period
of time [9]. The vulnerable population usually includes infants, children with increased
growth demands, menstruating girls and women, and pregnant women [4, 10]. It has
been estimated that about half of all pregnant women experience IDA [11], which causes
a heavy health burden due to its negative impact on children, coupled with effects on
brain development and functioning due to reduced oxygen delivery to tissues [12]. In
adults, IDA causes fatigue [13]. Furthermore, severe anemia at hemoglobin levels < 7
mg/dl can result in devastating outcomes, such as maternal mortality, reduced birth
weight, and reduced cognitive ability [10].
2.2. Common causes of iron deficiency in LMICs
The populations in the LMICs are usually characterized by nutritional deficiencies, low
iron-containing food, or problems in absorption of dietary iron due to viral and parasitic
infections, for example, malaria (since these pathogenic microbes consume iron as
well), and high prevalence of Helicobacter pylori infection [14]. Moreover, IDA may arise
secondary to partial gastrectomy, coeliac disease, Crohn’s disease, some drugs that
reduce iron absorption [15], hemorrhage associated with childbirth, or heavy menstrual
blood loss. It can also result secondary to impaired absorption due to high intake of
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phytate that impairs iron absorption or altered nutrient metabolism [12]. Malnutrition
causes a wider segment of the population in LMICs to be at risk of IDA.
A recently identified risk factor for IDA is oxidative stress induced by high unbound
iron that eventually damages erythrocytes and results in IDA [16, 17].
2.3. Iron: An integral component for cellular functions
Iron is a biologically essential component for all living organisms. In humans, it exists
as protein-bound, heme compounds, which include hemoglobin containing 25% of the
body iron and myoglobin containing 15% [18], or non-heme compounds like transferrin
and ferritin [19]. Heme enzymes and other iron-containing enzymes are involved in
electron transfer and oxidation-reduction processes [20]. The human body obtains iron
from three sources: environment (mother to fetus), recycled or mobilized form from iron
storage sites (major source), and diet (limited source) [21–25].
The quantity of iron in the body is well-regulated and tightly controlled through a
robust network at both cellular and systemic levels [26]. Most of the iron in the body
is recycled and reserved within the body, leaving only a small quantity to be acquired
exogenously either from diet or iron supplements with limited bioavailability [27].
Iron has always shown to be an intricate element in conflicting mechanisms. Iron
can be described as beneficial as a micronutrient, as well as harmful to body tissues
as a catalyst in a series of reactions that produce the toxic reactive oxygen species
(ROS) [26, 28]. Therefore, both iron deficiency and overload can have serious health
effects [29]. This paradoxical role has always confronted scientists regarding the body’s
mechanisms to coordinate iron delivery to tissues [30, 31].
To understand the biochemical mechanisms involved in iron absorption and the
various factors associatedwith these processes, two facts should be considered. Most of
the iron in the body is reserved within the body and recycled from different storage sites,
including senescent erythrocytes to other tissues. This implies that iron from exogenous
sources has very limited bioavailability [27]. This entails that iron trafficking requires
effective tissue communication and orchestration between the iron consuming cells,
for example, erythrocyte precursors, and the iron storage sites, for example, duodenal
enterocytes, hepatocytes, and tissue macrophages [2].
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2.4. Absorption of iron from the gut
Absorption is the most important mechanism in iron haemostasias [7]. Iron haemostasias
has been described in the literature as a partially understood process. Therefore, it has
been subjected to extensive research for decades to fill the gaps of knowledge about
its absorptive mechanisms [2].
Dietary iron is available in twomain forms: organic haem iron and non-haem inorganic
iron [4, 32]. The non-haem inorganic iron is available mostly in oxidized ferric form
besides its availability in its reduced ferrous form [33]. The duodenum and upper jejunum
have long been identified as the absorptive sites for iron [22]. Initially, ferrous iron is
up-taken in the gut by the enterocytes through the protein carrier DMT-1 [20], while
ferric iron is reduced to ferrous before being up-taken or carried by a different pathway
(mobilferrin–integrin) [32]. The ferrous complex with DMT-1 is influenced and regulated
to a great extent by iron deficiency, whereas the ferric–mobilferrin–integrin complex is
not [23].
Iron exits from the enterocytes into the plasma via the export protein ferroportin
[19, 27], and it is then carried by transferrin to either fuel erythropoiesis in the bone
marrow or to be stored in ferritin [27]. Eventually, the quantity of iron that actually
reaches plasma is the iron released from the enterocytes as transferrin-bound iron via
ferroportin and not that up-taken by the enterocytes from the gut [34].
The level of amount of iron absorbed is maintained by cellular and systemic pathways
[35]. At the cellular level of the mucosal block, large quantities of iron are detained by
enterocyte ferritin, a natural nano-protein mucosal acceptor. Thus, one ferritin molecule
cages 4,500 iron atoms [15, 25], while the excess iron stored in ferritin eventually gets
unloaded in the gut when enterocytes get sloughed at the end of their life span [36].
Signaled by the quantities of intracellular iron [23, 27, 32, 37–39], a reduction in brush
border enzymes occurs resulting in inhibition of iron absorption for more than 4–5 hr
after a single oral iron dose [39]. The systemic protective mechanism against excess
iron is controlled by hepcidin. Therefore, we will elaborate on the important discovery
of hepcidin as a safety gauge.
Inside the cell, an important fraction of iron known as labile iron pool (LIP) remains
bound to low molecular weight chelates, such as citrates, adenosine triphosphate,
ascorbic acid, or pyrophosphate. Usually, LIP represents <5% of total cellular iron at
iron blood level of 50–100 µM [26], however, its quantity may rise substantially by the
induction of certain biochemical stimuli, such as iron overload or iron levels that exceed
cell haemostasias [26, 30].
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2.5. Gauging iron absorption (inhibition vs enhancement)
Exogenous iron absorption is largely dictated by the body’s iron requirement [23].
Consequently, the absorption of iron from the gut or mobilization from storage sites
is accelerated by plasma iron turnover to produce more erythrocytes in response to
stimulation by the erythropoietin hormone [2, 23]. Nevertheless, absorption of iron
is influenced by many other factors and substances coexisting in the gut, either by
inhibition or enhancement. Enhancers include ascorbic acid, meat, and poultry, while
inhibitors are tannins, dairy products, polyphenols, and phytates [40, 41], as well as
some trace elements like zinc and copper, which are found in the enzymes involved in
iron metabolism [12, 41].
2.6. Damaging role of oxidative stress triggered by free (unbound)
iron
LIP is chelatable transient iron and a critical factor in producing catalytic iron that
generates ROS and nitrogen species through the Haber–Weiss reaction [26, 28], which
is responsible for initiating the Fenton’s reaction [30, 42]. Fenton’s reaction is consid-
ered as a major mechanism for generating ROS in biological systems [43]. It causes
corruption of the lipid membranes, proteins, and DNA [44]. Peroxidation of membrane
lipids can damage the membrane structure, decrease the cell deformability, enhance
immunoglobulin-G binding, and complement activation [45]. This damage promotes a
state of oxidative stress [26, 37], and eventually leads to degradation of erythrocytes
that damages tissues and organs [15, 16]. Oxidative stress can be induced by high intake
of iron during iron supplementation with doses that exceed the capacity of endogenous
antioxidant proteins (e.g., glutathione), which could lead to the generation of ROS. This
could result in tissue damage, specifically of the intestinal mucosa that is vulnerable to
oxidative damage [45], inflammation of the colon, and disturbances of the microbiome
[46].
Generally, our body is capable of detoxification and neutralization of ROS by the
naturally occurring endogenous antioxidants to restore the pro-oxidants–antioxidants
balance and prevent the damage of oxidative stress. Moreover, other natural protective
mechanisms exist to prevent the oxidative stress related to free unbound iron through
hepcidin and chelation of LIP iron [30, 35, 42].
Recently, there has been equivocal evidence about the important role of oxidative
stress in the pathophysiology of IDA through increased free cellular iron [47] and the
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systemic and cellular handling of iron haemostasias [27, 39, 48, 49]. This new knowledge
causes the co-ingestion of exogenous antioxidants to become a rational adjunctive to
iron therapy [50].
2.7. Strategies to control iron-deficiency anemia
The persistence of IDA as a worldwide health problem requires a novel and innovative
interventional approach by the provision of appropriate and bioavailable forms of iron
dosage that avoid iron toxicity. Meanwhile, several constraints exist in the resources
of poor health settings in LMICs, including proper diagnosis, prevention, and effective
management of IDA. Iron replete is crucial for healthy development of children and
the well-being of all people in LMICs. Therefore, it is especially important to develop
strategies mainly addressing LMICs to protect such vulnerable populations from the
negative impacts of IDA.
Historically, there were different approaches to control IDA, including food fortification
and iron salts supplementation [51]. Despite the continuous efforts by various interna-
tional organizations to come up with appropriate guidelines on iron supplementation,
and more than 17 guidelines proposed by the World Health Organization alone [12],
none of these guidelines are based on evidence-based clinical study.
Implementation of anemia control programs in LMICs requires careful baseline epi-
demiologic evaluation to select the appropriate interventions that suit the most affected
populations, in line with the currently available scientific evidence to ensure safety and
effectiveness [5].
To meet iron requirements in LMICs where iron deficiency is widespread, adequate
intervention programs are recommended. However, iron is known to influence the
pathogenesis of a number infectious disease (e.g., malaria), which are especially com-
mon among the populations of the LMICs [51, 52]. Earlier evidence has already demon-
strated the dose-related deleterious effect of iron therapy in malaria endemic regions
[53].
In some of the LMICs with a high malaria burden, hepcidin blocks iron absorption
from the gut as well as inhibits its mobilization, resulting in prevention of efficient iron
uptake. This means that iron supplementation in malaria endemic areas would be less
effective [34]. This represents a challenge for policy-makers, and the urgent need to
develop efficient therapeutic approaches with minimal infection-related risks. Moreover,
it requires individualizing the therapeutic regimen according to iron deficiency, infection
risk, and inflammatory status of the individuals [52].
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2.8. Pathophysiology of iron-deficiency anemia
Iron deficiency develops gradually in states of negative iron balance in three stages. It
typically evolves through storage iron depletion (latent anemia), iron-deficient erythro-
poiesis, and finally overt iron-deficiency anemia (defined as concomitant iron deficiency
plus anemia) [54].
2.9. Diagnosis of iron-deficiency anemia in LMICs
The most commonly used indicator of IDA in many poor resource settings like the LMICs
is hemoglobin. However, to confirm iron deficiency in patients with low hemoglobin, a
low serum ferritin level must be established [10, 55]. In cases of coexisting infectious
disease and/or inflammation, serum ferritin, which is an acute phase reactant, may give
false results [56], because its levels increase in infection and/or inflammation [12, 57]. In
such situations, a simpler approach that optimally uses serum ferritin in IDA diagnosis is
considering values <15 μg/dl as diagnostic for IDA and those >100 μg/dl to rule out IDA
[58]. Alternatively, other inflammatory markers should be included in the assessment,
such as C-reactive protein and alpha-1 glycoprotein [12], considering that transferrin
saturation is a very sensitive parameter to evaluate body iron stores [45].
IDA should be classified to determine its severity for appropriately guided therapy.
There are a number of cut-off values for hemoglobin to determine severity of IDA, for
example, mild IDA at hemoglobin of 10–10.9 g/dl, moderate IDA at hemoglobin level of
7–9.9 g/dl, and severe IDA at levels <7 g/dl [13].
2.10. Iron supplementation scheme
After a confirmed IDA diagnosis, the longstanding trend of treatment is iron supplemen-
tation either by oral or intravenous route. The choice is largely dependent on factors
such as the patient’s age, sex, severity of anemia, and timeframe for acceptable iron
correction [59].
The orthodox treatment of IDA to replenish the iron stores fully is oral administration
of 100–200 mg elemental iron twice per day [39, 60], for three months [4, 54]. The
oral route has always been the first-line choice due to its safety, cost-effectiveness, and
convenience [61]. Frequently used oral iron salts, such as ferrous fumarate, ferrous sul-
phate, and ferrous gluconate, have similar bioavailability and slightly different elemental
iron content [60].
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2.11. Current debate on iron therapy practice
The magnitude and spacing of oral iron dose are becoming issues of great concern
and controversy due to the inefficiency and toxicity of the iron dose in use [27, 39].
Based on the discovery of hepcidin, Moretti et al. have questioned the need for large
daily doses of iron as compared to the much smaller dose of bioavailable iron at 12.5%
of the dose. This has raised safety concerns regarding the potential risk of oxidative
stress and involvement of unbound iron in Fenton’s reaction [26, 61]. This concern has
been addressed and consolidated experimentally for the first time by a good evidence-
based clinical trial [39]. It is necessary to remember that pregnant women are among
the vulnerable groups for IDA due to the higher risk of potential iron toxicity related to
oxidative stress that is associated with the mitochondria-rich placenta [61].
Oral iron salts remain the standard IDA treatment option in current use, associated
with dose-dependent toxicity [57], and subsequently have been known to compromise
compliance to treatment. Therefore, there is a need for a better and safer treatment
options to replenish iron stores in IDA patients.
2.12. Call for a safer and more effective iron therapy
The oral route remains the first-line choice in the wider population of patients [46].
Its advantages include cost-effectiveness and ease of monitoring, especially in health
settings with limited resources [64]. The challenge for IDA treatment in the poor-resource
settings of LMICs are facing many constrains with respect to the diagnosis, prevention,
and treatment of IDA. Effective management often requires treatment of the underlying
cause prior to iron supplementation, restoration of hemoglobin to normal levels, and
treatment of complications if they exist [65].
Many reviews and studies have concluded that there is an urgent and compelling
need to revisit the iron therapy guidelines that are currently in use [65, 66]. Some have
proposed recommendations for safer regimens [39, 45, 65]. Recent reviews are in favor
of smaller iron doses and intermittent dosing rather than daily doses [67].
With respect to iron supplementation, it is important to bear in mind that certain
individuals may be at a higher risk with high iron doses, such as severely ill patients with
inflammatory diseases [68], IDA patients with chronic renal diseases [69], and patients
with underlying infections or malignancy [70]. In such patients, iron supplementation
may be deleterious and/or even harmful [70].
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3. Conclusion
The discovery of hepcidin and its role in IDA should be considered as a turning point
in iron therapy and a great advance in our knowledge about IDA. It is of paramount
importance to consider this in therapeutic decisions while determining the iron dose,
spacing, and duration, to avoid inefficiency of iron bioavailability, for example, twice per
week or intermittent dosing. Furthermore, the potential of high iron supplementation to
increase free unbound iron and fuel the deleterious effect of catalyst iron in Fenton’s
reaction is indicative of the need to reduce the iron dose magnitude.
From the aforementioned information, it can be concluded that whatmattersmost with
iron therapy is not iron replete, but rather the iron supplementation with an appropriate
methodology.
Development of efficient and rational iron therapy program in LMICs should be done
through individualized approaches with special concern to the widespread infection-
related health issues, for example, malaria, tuberculosis, and HIV infections, which have
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